SCHEMBL5378284

SCHEMBL5378284

CSc1nsc(OCc2c(F)cccc2F)n1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.39
MAPK1 P28482 2/20 0.39
KMT2A Q03164 8/20 0.34
MEN1 O00255 5/20 0.34
TSHR P16473 4/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPC1 O15118 1/20 0.32
PIK3CG P48736 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13382007 0.80 KMT2A (0.33) TDP1KMT2AMEN1RAB9AALDH1A1
SCHEMBL5378771 0.78 TDP1 (0.56) TDP1MAPK1KMT2AMEN1RAB9A
SCHEMBL5377736 0.78 LMNA (0.47) TDP1MAPK1KMT2AMEN1TSHR
SCHEMBL5375933 0.76 RAB9A (0.38) TDP1MAPK1KMT2AMEN1TSHR
SCHEMBL5381717 0.75 KMT2A (0.39) TDP1MAPK1KMT2AMEN1TSHR
SCHEMBL5381751 0.74 SYK (0.46) RAB9ASMN1; SMN2ALDH1A1NPC1
SCHEMBL4799608 0.74 SMN1; SMN2 (0.42) TDP1MAPK1KMT2AMEN1TSHR
SCHEMBL5378057 0.74 KDM4E (0.46) KMT2AMEN1CYP1A2CYP2C9CYP2C19
SCHEMBL5417437 0.74 MEN1 (0.41) TDP1MAPK1KMT2AMEN1TSHR
SCHEMBL5378069 0.74 CYP1A2 (0.47) TDP1MAPK1KMT2AMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-20050215578-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-09-29 US disclosed
EP-1475374-A1 THIADIAZOLE COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215578-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH TDP1 1173/4885MAPK1 509/4885KMT2A 2219/4885
US-20070293510-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH TDP1 1150/4885MAPK1 488/4885KMT2A 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.